Scholars Central

Conference abstractPublished 31 Mar 2016

Nephroprotection by hypoglycemic agents: Do we have supporting data?

Authors: Jose Luis Gorriz, Javier Nieto, Juan F Navarro-Gonzalez, Pablo Molina, Alberto Martinez-Castelao, Luis M Pallardo

Universidad de Valencia, Spain Hospital General Universitario de Ciudad Real, Spain Hospital Universitario N S Candelaria, Spain Hospital Universitario Bellvitge, Spain Spanish Society of Nephrology, Spain Carlos III Researc

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomplete. There is a scarcity of studies analyzing the nephroprotective effect of antihyperglycemic drugs beyond their glucose lowering effect and improved glycemic control on the prevention and progression of diabetic nephropathy. This article analyzes the existing data about older and newer drugs as well as the mechanisms associated with hypoglycemic drugs apart from their well-known blood glucose lowering effect in the prevention and progression of diabetic nephropathy. Most of them have been tested in humans but with varying degrees of success. Although experimental data about most of antihyperglycemic drugs has shown a beneficial effect in kidney parameters, there is a lack of clinical trials that clearly prove these beneficial effects. The key question, however, is whether antihyperglycemic drugs are able to improve renal end-points beyond their antihyperglycemic effect. Existing experimental data are post hoc studies from clinical trials and supportive of the potential renal-protective role of some of them, especially in the cases of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors. Dedicated and adequately powered renal trials with renal outcomes are necessary to assess the nephrotection of antihyperglycemic drugs beyond the control of hyperglycemia.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Nephrology & Therapeutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nephrology & Therapeutics
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Jose Luis Gorriz”
  • BylineArticles whose byline prints “Javier Nieto”
  • BylineArticles whose byline prints “Juan F Navarro-Gonzalez”
  • BylineArticles whose byline prints “Pablo Molina”
  • BylineArticles whose byline prints “Alberto Martinez-Castelao”
  • BylineArticles whose byline prints “Luis M Pallardo”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels